Danone SA has expanded its focus on gut health and biotic research by acquiring The Akkermansia Company $(TAC)$, a Belgian firm with nearly two decades of expertise in the field. TAC is renowned for its discovery and development of the biotic strain Akkermansia muciniphila MucT™, which has been clinically shown to enhance the gut barrier, reduce inflammation, and address metabolic disorders such as obesity, diabetes, and cardiovascular disease. This acquisition is part of Danone's Renew strategy, which emphasizes scientific innovation and meeting the growing consumer demand for health-focused products.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。